Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cabazitaxel in AR-V7-positive metastatic castration-resistant prostate cancer
2016-002993-11Phase 2Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Nov 2016
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Erasmus MC Cancer Institute. Primary endpoint: PSA response rate. Started Nov 2016; status: active.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002993-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002993-11.